Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1391&sort=-funder_divisions
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder_divisions", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-funder_divisions", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-funder_divisions", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1390&sort=-funder_divisions" }, "data": [ { "type": "Grant", "id": "9235", "attributes": { "award_id": "5U18FD006993-02", "title": "Assessment of Zoonotic Risk of Emerging Infections in Companion Animals", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-15", "end_date": "2025-08-31", "award_amount": 220657, "principal_investigator": { "id": 24972, "first_name": "Laura Brunengraber", "last_name": "Goodman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 279, "ror": "https://ror.org/05bnh6r87", "name": "Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24973, "first_name": "Michael J", "last_name": "Stanhope", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 279, "ror": "https://ror.org/05bnh6r87", "name": "Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This project evaluates the zoonotic implications of two important possible pathogens of companion animals: E. coli and coronaviruses. E. coli is the most common pathogen tested for antibiotic susceptibility in veterinary diagnostic labs. It is also one of the most concerning for multi-drug resistance; several isolates captured thus far in Vet-LIRN active surveillance are predicted to be pan-resistant to all drugs used in human or animal medicine. Our group has published the first animal host specific E. coli virulence database compatible with tools that can mine whole genome sequencing data. We now propose a comparative evolutionary genomic study to assess the potential of E. coli in dogs to encode novel resistance mechanisms and cause disease in humans. The data will be explored employing the latest developments in bacterial pan- genomic analysis, as well as bacterial GWAS. Such analysis will reveal if there are E. coli loci adapted to dogs, whether such loci have the functional character suggestive of pathogenic potential, and whether dogs may be a reservoir of potential pathogenesis or antibiotic resistance. The present outbreak of coronavirus disease caused by SARS-CoV-2 (COVID-19) is the third documented spillover of an animal coronavirus to humans to have resulted in a major epidemic, within the past two decades. Characterizing the species diversity of coronaviruses from companion animals, represents an important necessary step towards improving our understanding of virus–host interactions and to enhance our preparedness for future outbreaks. We will undertake this characterization in three different host species – horses, cats, and dogs – making use of an extensive set of time series samples (respiratory and feces) that comprise the AHDC’s collection. Sequences of coronavirus genomes will be acquired using two approaches: RNAseq of the respiratory virome and multiplexed amplicon approaches of both respiratory and feces samples; the former will allow us to identify the coronavirus species repertoire of each host, including the identification of any new coronavirus species, the latter will provide the ability to explore aspects of diversity in detail, within and between hosts. Comparative evolutionary genomic analyses of the data will inform on a wide variety of issues related to their zoonotic potential, including for example: (1) Which coronavirus species are more prone to inter-host transmission and is there a directionality to that transmission? (2) Are their host reservoirs for any of the virus species? (3) Which have a history of recombination? (4) Which have a history of molecular adaptation and what viral proteins does that involve? Our final aim is to provide eight other Vet-LIRN sequencing laboratories with the reagents and training to be able to independently sequence and analyze bacterial and viral genomes, including SARS-CoV-2. All three Aims of this project directly support the mission of the FDA to ensure the safety of our nation's food supply and protect public health.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9236", "attributes": { "award_id": "1U18FD006993-01", "title": "Assessment of Zoonotic Risk of Emerging Infections in Companion Animals", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-15", "end_date": "2025-08-31", "award_amount": 125600, "principal_investigator": { "id": 24972, "first_name": "Laura Brunengraber", "last_name": "Goodman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 279, "ror": "https://ror.org/05bnh6r87", "name": "Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24973, "first_name": "Michael J", "last_name": "Stanhope", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 279, "ror": "https://ror.org/05bnh6r87", "name": "Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This project evaluates the zoonotic implications of two important possible pathogens of companion animals: E. coli and coronaviruses. E. coli is the most common pathogen tested for antibiotic susceptibility in veterinary diagnostic labs. It is also one of the most concerning for multi-drug resistance; several isolates captured thus far in Vet-LIRN active surveillance are predicted to be pan-resistant to all drugs used in human or animal medicine. Our group has published the first animal host specific E. coli virulence database compatible with tools that can mine whole genome sequencing data. We now propose a comparative evolutionary genomic study to assess the potential of E. coli in dogs to encode novel resistance mechanisms and cause disease in humans. The data will be explored employing the latest developments in bacterial pan- genomic analysis, as well as bacterial GWAS. Such analysis will reveal if there are E. coli loci adapted to dogs, whether such loci have the functional character suggestive of pathogenic potential, and whether dogs may be a reservoir of potential pathogenesis or antibiotic resistance. The present outbreak of coronavirus disease caused by SARS-CoV-2 (COVID-19) is the third documented spillover of an animal coronavirus to humans to have resulted in a major epidemic, within the past two decades. Characterizing the species diversity of coronaviruses from companion animals, represents an important necessary step towards improving our understanding of virus–host interactions and to enhance our preparedness for future outbreaks. We will undertake this characterization in three different host species – horses, cats, and dogs – making use of an extensive set of time series samples (respiratory and feces) that comprise the AHDC’s collection. Sequences of coronavirus genomes will be acquired using two approaches: RNAseq of the respiratory virome and multiplexed amplicon approaches of both respiratory and feces samples; the former will allow us to identify the coronavirus species repertoire of each host, including the identification of any new coronavirus species, the latter will provide the ability to explore aspects of diversity in detail, within and between hosts. Comparative evolutionary genomic analyses of the data will inform on a wide variety of issues related to their zoonotic potential, including for example: (1) Which coronavirus species are more prone to inter-host transmission and is there a directionality to that transmission? (2) Are their host reservoirs for any of the virus species? (3) Which have a history of recombination? (4) Which have a history of molecular adaptation and what viral proteins does that involve? Our final aim is to provide eight other Vet-LIRN sequencing laboratories with the reagents and training to be able to independently sequence and analyze bacterial and viral genomes, including SARS-CoV-2. All three Aims of this project directly support the mission of the FDA to ensure the safety of our nation's food supply and protect public health.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9256", "attributes": { "award_id": "3U01FD007064-01S1", "title": "Assessing the impact of COVID-19 on opioid crisis and incorporating it in the FDA's opioids systems model", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24987, "first_name": "Lucas", "last_name": "Glos", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-01", "end_date": "2021-08-31", "award_amount": 249950, "principal_investigator": { "id": 24988, "first_name": "Mohammad S.", "last_name": "Jalali", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this project is to expand FDA's current opioids systems model to enable multidimensional outcomes and cost-effectiveness analyses. Steep increases in opioid misuse and disorder, overdoses, and deaths since the 1990s represent a public health crisis with far-reaching impacts on society. Rising OUD and overdose deaths are linked with the decline in life expectancy in the United States each year from 2015 to 2017, which was the first multi-year decrease since 1993. While mortality is clearly an important outcome to consider when analyzing the effects of a policy, decision makers and stakeholders also care about how policies affect other outcomes that matter to society. This project will expand FDA's opioids systems model to include additional outcomes and enable cost-effectiveness analyses of policies and interventions meant to reduce opioid misuse, OUD, and overdose. We will develop the proposed model expansion as a team of experts with extensive experience in health economics and outcomes research, simulation modeling, and substance use disorder health science and policy. We will first expand the model to include additional impacts of opioid misuse, OUD, and overdose on quality of life and productivity loss, and societal costs to criminal justice and health care systems (Aim 1). We will then estimate costs and examine both intended and unintended outcomes associated with interventions and policy changes meant to reduce misuse, OUD, and fatal and non-fatal overdose (Aim 2). Finally, we will examine potential policy strategies under the frameworks of effectiveness and cost-effectiveness analyses. In these analyses, we will compare the effectiveness and cost-effectiveness of combinations of interventions and policies meant to reduce opioid misuse, OUD, and overdose (Aim 3), such as implementation of prescription controls, expanded access to MOUD, and increased distribution of naloxone. These aims will ultimately deliver: 1) an expanded model that is able to represent new outcomes as well as costs; 2) insight for policymakers regarding how various combinations of policy options will affect these multidimensional outcomes; and 3) the ability to discern which policy options represent the most efficient allocation of resources while minimizing unintended consequences. The proposed model expansion and accompanying analyses will enable FDA's policy tool to broaden the lens through which FDA and other government agencies consider the impact of policy solutions meant to reduce opioid misuse, OUD, and overdose.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8767", "attributes": { "award_id": "1U01IP001156-01", "title": "Enhanced Surveillance for New Vaccine Preventable Diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2026-08-31", "award_amount": 1441645, "principal_investigator": { "id": 24567, "first_name": "NATASHA Bassam", "last_name": "HALASA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "- Mandatory Component A Acute respiratory illness (ARI) and acute gastroenteritis (AGE) are the leading causes of death worldwide in young children. Established leading viral etiologies of AGE are rotavirus and norovirus and respiratory syncytial virus (RSV) and influenza virus for ARI. Our understanding of ARI and AGE epidemiology is constantly changing due to spatiotemporal fluctuations, discovery of new or re-emerging pathogens [e.g. enterovirus D68 (EV-D68) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)], and use of rotavirus and influenza vaccines. Hence, surveillance efforts are imperative to define ARI and AGE disease burden, causative pathogens, outcomes, and vaccine impact. The primary influenza prevention strategy in the United States is vaccination for all individuals six months or older. There is a paucity of data regarding vaccine effectiveness (VE) against laboratory-confirmed influenza in children, and influenza viruses and vaccine antigenic components change annually. Therefore, perpetual assessments of VE are needed to monitor the impact of influenza vaccination on disease and inform strategies to improve magnitude, durability, and breadth of protection. Pediatric SARS-CoV-2 vaccines are an urgent public-health priority and likely will become available on an accelerated timeline in an effort to curb the COVID-19 pandemic. Rigorous, prospective surveillance of SARS-CoV-2 VE is crucial to support reliance on vaccines as primary prevention. Thus, the first main objective of this project is to conduct population-based active surveillance for respiratory and enteric viral pathogens in pediatric inpatient and emergency department settings and asymptomatic controls. Our team of Vanderbilt investigators is highly experienced in conducting prospective, population- based ARI and AGE surveillance. We propose to conduct ARI and AGE surveillance with the following specific aims: 1) To perform prospective, active surveillance to determine the etiology and burden of inpatient and emergency department (ED) acute viral respiratory and enteric diseases among the pediatric population. 2) To characterize the clinical and epidemiologic factors of pediatric infections (including in asymptomatic children) through active surveillance. 3) To evaluate vaccine effectiveness and impact of vaccines and other interventions (e.g., immunoprophylaxis with antiviral agents or other therapeutics) available or projected to become available during the period of performance. The second main objective of this project is to conduct surveillance and epidemiologic characterization of acute flaccid myelitis syndrome in children. Given the epidemiologic connection between EV-D68 infection and acute flaccid myelitis (AFM), it will be important to conduct rigorous, active, longitudinal surveillance for AFM across multiple consecutive seasons; carefully define AFM clinical spectrum, risk factors, incidence rates, and laboratory parameters; and document local circulation of EV-D68 and other ARI and AGE pathogens coincident with increased AFM occurrence. This work underpins development of preventive, diagnostic, and therapeutic strategies for AFM.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8775", "attributes": { "award_id": "1R01CE003347-01", "title": "Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24575, "first_name": "Amanda", "last_name": "Garcia-Williams", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-30", "end_date": "2024-09-29", "award_amount": 362481, "principal_investigator": { "id": 24576, "first_name": "Sean P", "last_name": "Hennessy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The US drug overdose epidemic in the has grown dramatically in the past twenty years, with more than 70,000 fatal drug overdoses in 2019 alone. This growth in overdose deaths is a major contributor to the multiyear decline in US life expectancy that was seen even before the COVID-19 pandemic began. The drugs responsible for the largest increases in overdose deaths are synthetic opioids, cocaine, and other stimulants (primarily methamphetamine). In recognition of the increasing role that cocaine and other stimulants are playing in the drug overdose epidemic, the US Centers for Disease Control and Prevention (CDC) has called for increased surveillance and evidence-based prevention and response strategies to address overdoses involving these agents. While rates of stimulant use and overdose have been reported vary by demographics, physical and mental health conditions, disability, and other factors, no prior research has linked individual-level data on demographics, disability, and social determinants of health together with granular measures derived from healthcare utilization records, with comprehensive, area-level data on social deprivation to develop knowledge about risk and protective factors for stimulant overdose. Further, no prior research has focused on stimulant overdose in Medicaid enrollees, a large, vulnerable, underserved population in whom half of all amphetamine-related hospitalizations occur. This project addresses Objective 2 of RFA-CE-21-002: to assess risk and protective factors for illicit stimulant use, use disorder, or overdose that can contribute to the development or adaptation of intervention strategies. The study will 1) develop and validate a model using both person-level characteristics (including demographic characteristics, household income, diagnoses, prescriptions, and healthcare utilization) and area-level characteristics (including a wide range of measures of socioeconomic deprivation) to identify, among Medicaid enrollees age 15 and older, who is at highest risk of an emergency department (ED) encounter for overdose from cocaine or other stimulants; 2) develop and validate a model to identify, among those Medicaid enrollees age 15 and older at highest risk of an ED encounter for stimulant overdose, when they are at highest risk; and 3) among those Medicaid enrollees age 15 and above with a prior ED encounter for stimulant overdose, to measure the rate of and identify risk and protective factors for a subsequent ED encounter for overdose from stimulants and/or opioids. The results will be useful in at least two ways. First, they will provide generalizable knowledge about the individual-level and social factors that predispose to or protect against stimulant overdose. Such etiologic factors can then be the targets of intervention at the national, state, county, and local levels to ameliorate the effects of these causes, as well serve as the basis of future research to better understand the underlying causal mechanisms. Second, the results can be used pragmatically to identify high-risk individuals for the purpose of targeting scarce resources for evidence-based approaches to overdose prevention.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8805", "attributes": { "award_id": "1R43IP001163-01", "title": "Rapid SARS-CoV-2 Spike Protein Neutralizing Antibody Tests for Evaluating COVID Vaccine-Generated Immunity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-30", "end_date": "2022-03-31", "award_amount": 242132, "principal_investigator": { "id": 24610, "first_name": "Suiqiong", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1761, "ror": "", "name": "DL ADV-TECH, LLC", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1761, "ror": "", "name": "DL ADV-TECH, LLC", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Summary/Abstract: The availability of COVID-19 vaccines is a significant step in ending this pandemic and returning life to normal. Successfully vaccination should induce sufficient titers of specific neutralizing antibodies (nAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to prevent infection of COVID-19. SARS-CoV-2 spike protein nAbs test will be essential to verify whether the recipients have sufficient protection and determine the duration of immunity. Conventional SARS-CoV-2 spike protein nAbs test, such as plaque reduction neutralization test and ELISA, are laboratory based, which are not suitable for large scale measurement. While lateral flow assays can provide cheap and quick tests, current lateral flow test strips can’t provide accurate quantitative measurement. In this SBIR project, DL ADV-Tech proposes to develop a highly sensitive, reliable and rapid SARS-CoV-2 S-protein nAbs testing device for quantification of nAbs concentrations. The major significance of this proposed approach is the ability to accurately, quickly and massively quantify SARS-CoV-2 S-protein nAbs by leveraging our advanced mesoporous nanoflowers (MNFs) signal amplification technique (patent pending) and smartphone-based readout technique. Recently we discovered a new class of catalytic nanomaterials, bimetal Pt-Pd MNFs, with impressive peroxidase-like catalytic activity and excellent stability under harsh conditions. Our patent pending “bimetal MNFs-based lateral flow immunoassays” demonstrated Pt-Pd MNFs can improve the sensitivity by 1000 times over commercial colloidal gold labels. The tremendous activity of MNFs is of particular importance to make this proposed test platform substantially more compelling for improvement of accuracy in rapid analysis. Meanwhile, the chromatic results from the lateral flow strips will be acquired and analyzed using a smartphone readout, which allows rapid and accurate quantification of SARS-CoV-2 S-protein nAb concentrations. Integrated with smartphone, this testing device will provide quantitative measurements and easy operation, and allow real-time data collection and sharing. The proposed testing device allows highly reliable, simple, robust and quantitative measurement of SARS-CoV-2 S-protein nAbs in blood, providing a powerful tool to accurately and closely monitor SARS-CoV-2 S-protein nAbs levels at a large population scale and offering more confidence to individuals and clinicians to fight this pandemic. In Phase I, the key focus is to prove the concept of rapid quantification of SARS-CoV-2 S-protein nAbs on the proposed testing device, and demonstrate the feasibility of the testing device in blood samples in terms of sensitivity, accuracy and detection range. The Pt-Pd MNFs enhanced smartphone platform is expected to have high accuracy (< 5% RSD) for SARS-CoV-2 S-protein nAbs quantification (1ng/ml – 100ug/ml). In phase II, the tests will be evaluated using clinic samples and further optimized for real-world applications. The proposed testing device, once validated, will greatly benefit public health in the U.S. as well as worldwide. There is a large market and significant commercial opportunity for such an effective testing device. 1", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8808", "attributes": { "award_id": "1U18FD007520-01", "title": "Building testing capacity for past and current SARS-CoV-2 infection in animals with potential exposure to humans with COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-15", "end_date": "2022-09-30", "award_amount": 83739, "principal_investigator": { "id": 24612, "first_name": "Ailam Lee", "last_name": "Lim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this proposal is to build testing capacity at the Wisconsin Veterinary Diagnostic Laboratory (WVDL) to perform serology detection and whole genome sequencing of SARS- CoV-2 from animal samples. We are requesting funding for the purchase of reagents and equipment to validate the SARS-CoV-2 Surrogate Virus Neutralization Test kit (GenScript) as a multi-species diagnostic serology assay, with specific focus on the detection of antibodies against SARS-CoV-2 virus in companion animals. As part of a proposed Genomic Consortium, we are requesting funds to purchase a QIAxcel Adnavced System (Qiagen) and a MinION (Oxford Nanopore) Enhanced Pack to validate library preparation and sequencing kits for iSeq (Illumina) and MinION for targeted SARS-CoV-2 sequencing. We will participate in the development and validation of bioinformatics pipelines that will be made accessible to veterinary diagnostic personnel to quickly and efficiently determine genomic lineages, and develop a staff training and development program to maintain proficiency in sequencing and to analyze the SARS-COV-2 genome. Together, we aim to have a validated multi-species serological diagnostic assay and trained staff with streamline workflow for whole genome sequence of the SARS-CoV-2 virus detected in animal specimens, to increase our capacity and capability to support diagnostic activities for the ongoing global SARS-CoV-2 pandemic. In turn, the acquired equipment and training will help building WVDL’s readiness to response to potentially other important future veterinary disease outbreaks that are important to human food safety and animal welfare.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8811", "attributes": { "award_id": "1U19OH012303-01", "title": "Carolina Center for Total Worker Health and Well-being", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24486, "first_name": "Maria", "last_name": "Lioce", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2026-08-31", "award_amount": 1097349, "principal_investigator": { "id": 24613, "first_name": "LAURA A", "last_name": "LINNAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "More than 63% of US adults are employed, and work exerts an independent, powerful influence on their health. At UNC Chapel Hill, our recognition of the role of work in health has driven our long history of occupational safety and health promotion activities, including surveillance, basic etiology, intervention and translation research, practice, and influence on public policy. As we conducted needs and strengths assessments in preparation for this Center proposal, we saw how the COVID-19 pandemic created a massive re-shaping of work, work conditions, and worker health – particularly related to mental health and well-being among essential workers. This observation created tremendous interest among investigators at UNC Chapel Hill, the NC Occupational Safety and Health Education Research Center, UNC's Center for Health Promotion and Disease Prevention and Injury Prevention Research Center, collaborators at Duke University and UNC Greensboro, and key stakeholders from public and private sectors to join forces to establish a new Carolina Center for Total Worker Health and Well-Being. The mission of the Carolina Center is to generate new knowledge and implement activities to improve worker health and well-being in North Carolina, the southeast region, and the nation. Strong leadership, national experts on our External Advisory Committee (EAC) and at RTI International will work with us to conduct the overall Center evaluation, with a goal of continuous quality improvement that informs strategic planning efforts. Within the Center's Pilot Project Program, we will employ data-driven approaches to prioritize proposals funded, be responsive to emerging issues, and support the work of the four proposed research projects which address three essential worker groups (nurses/physicians, firefighters and childcare) and an under-studied group of LGBTQ workers. Given the current and growing needs we identified, we will focus our attention on mental health and well-being of these workers, as well as traditional occupational safety outcomes such as slips, trips and falls. We will investigate different participatory approaches to engaging with workers and other stakeholders as we move the research enterprise from basic etiology and surveillance, to intervention and translation. Our Center's work directly addresses NORA and TWH Research Agenda priorities with important, innovative research, as well as outreach and education activities that will communicate the benefits of a TWH approach to businesses and key stakeholders, translate our findings and disseminate them to improve policy and practice, and build capacity for TWH among new and current occupational safety and health professionals through the expansion of our existing TWH certificate to non-degree seeking health professionals. As evidenced by enthusiastic letters of support from existing partners at UNC, our EAC members and others in Region 4, and several other TWH Center representatives, the Carolina Center is uniquely positioned to address the challenges of improving worker and workplace health in North Carolina, the southeastern region, and nationally.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8820", "attributes": { "award_id": "1R01FD007456-01", "title": "A Novel First-in-class 3D Printing Technology for Advanced Manufacturing of Complex Vaccine Formulations against Influenza and Emerging Infectious Diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24621, "first_name": "Manuel", "last_name": "Osorio", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2024-08-31", "award_amount": 498189, "principal_investigator": { "id": 24622, "first_name": "Mohammed", "last_name": "Maniruzzaman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 972, "ror": "", "name": "UNIVERSITY OF TEXAS AT AUSTIN", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 972, "ror": "", "name": "UNIVERSITY OF TEXAS AT AUSTIN", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY: Vaccination is known to be the most effective strategy to manage the spread and deleterious impact of various infectious diseases including the most recent emerging, coronavirus disease 2019, COVID-19. Recombinant protein subunit vaccines have demonstrated promising results for immunization against infectious diseases recently. These vaccines are manufactured through recombinant DNA technology in which the gene fragment that encodes the production of the recombinant protein is introduced to a host cell as an expression system. The genetically engineered cells can proliferate and produce a high amount of the protein of the target which can be separated and purified in the succeeding steps. The recent progress in genetic tool development to manipulate the microorganisms and utilization of mammalian cell lines in biopharmaceutical manufacturing have projected the global protein markets to reach $228.4 billion by the end of this year. However, this industry is still overloaded with processes that lack flexibility and process controls or integration needed for continuous or on demand production capacity. There is no biomanufacturing system that can produce recombinant proteins through a single-step continuous manufacturing process. So, due to the high demand for vaccines all over the world, there’s an immense need for highly efficient yet inexpensive technologies. Yeast expression systems such as Pichia pastoris (P. pastoris) can be used as an expression host cell which offers numerous advantages over traditional systems including high growth rate, easy genetic manipulation process, high yield protein expression, performing eukaryotic post-translational modifications, appropriate protein folding and protein secretion in the external medium and easy purification process.In this project we will utilise a novel Sprayed Multi Adsorbed-particle Reposing Technology (SMART 3D printing technique to produce biocompatible Pluronic (F127)-bisurethane methacrylate (F127-BUM) polymers based microcarrier immobilised with P. pastoris which can be used in large-scale fermentations for production of recombinant proteins. Our SMART technology meets the requirements for recombinant proteins manufacturing such as ease of scale-up, correct protein folding, and short post-production processing. It also has the potential to improve agility, flexibility, cost, and robustness in the manufacturing processes for complex protein-based biologics.Additionally, in contrast to other particulate fabrication techniques, SMART can incorporate live cells during the single-step microparticle formulation process. This technology can easily host further ancillary processes such as ultra-low temperature freezing print bed (-80oC or lower), fibre optic probes for the inline monitoring of critical product quality attributes (CQAs) such as viscosity, content uniformity and stability, making it accessible to industry in the near term with a robust control strategy. Our SMART will be implemented in a continuous setup to manufacture dry powder bioengineered P. pastoris encapsulated F127-BUM microcarriers to produce recombinant proteins for infectious diseases such as vaccines against Epstein-Barr virus (EBV) and influenza vaccines.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8831", "attributes": { "award_id": "1U18FD007508-01", "title": "Building testing capacity and sequencing capability for COVID-19 at Tifton Veterinary Diagnostic and Investigational Laboratory (TVDIL)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-15", "end_date": "2022-08-31", "award_amount": 115077, "principal_investigator": { "id": 24642, "first_name": "Yung-Yi", "last_name": "Mosley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project summary: Tifton Veterinary Diagnostic and Investigational Laboratory (TVDIL), located in southern Georgia, is a Level 1 branch Lab of National Animal Health Laboratory Network (NAHLN). As a veterinary diagnostic lab, our mission is to detect and report diseases in animals. However, during the COVID-19 pandemic, TVDIL obtained its Clinical Laboratory Improvement Amendments (CLIA) registration and started human COVID-19 testing to answer the needs of a reasonable turnaround time for our rural hospitals and clinics. Between July 2020 to June 30, 2021, over 27,000 COVID-19 real-time RT-PCR tests were performed by TVDIL. Despite the success of serving the local community, this human-testing experience helped us decide what could be done to prepare for COVID-19 testing surge in animal diagnostics, which has not been performed regularly during the pandemic due to state and federal restrictions. The goal of this proposal is to build additional surge capacity and sequencing capability for COVID-19 animal cases. To enhance surge capacity, we propose to acquire a liquid handling system and a real- time PCR system. For building next-generation sequencing (NGS) capability for SARS-CoV-2, we intend to invest consumable reagent & supplies for our newly obtained NGS sequencer as well as hire & train designated personnel for performing the NGS task. While additional equipment will increase the testing capacity instantaneously, sequencing capability relies on dedicated and fully trained staff to operate the NGS system. Ultimately, the testing capacity and sequencing capability built from this project can also be applied to other scenarios such as significant animal diseases outbreak or if there is ever a need to expand human COVID-19 testing in the future.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1391, "pages": 1419, "count": 14184 } } }